Japanese encephalitis
diseaseOn this page
Also known as Encephalitis, JapaneseJapanese B encephalitisJE
Summary
Japanese encephalitis (MONDO:0019209) is a disease and 65 clinical trials. Top therapeutic interventions include japanese encephalitis virus, inactivated, sodium chloride, and yellow fever vaccine. A subtype of mosquito-borne viral encephalitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Phenotypes (HPO): 82
- Clinical trials: 65
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.65 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
82 HPO clinical features (Orphanet curated; top 50 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002353 | EEG abnormality | Very frequent (80-99%) |
| HP:0002383 | Infectious encephalitis | Very frequent (80-99%) |
| HP:0000273 | Facial grimacing | Frequent (30-79%) |
| HP:0000298 | Mask-like facies | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002039 | Anorexia | Frequent (30-79%) |
| HP:0002069 | Bilateral tonic-clonic seizure | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002396 | Cogwheel rigidity | Frequent (30-79%) |
| HP:0002516 | Increased intracranial pressure | Frequent (30-79%) |
| HP:0002922 | Increased CSF protein concentration | Frequent (30-79%) |
| HP:0003202 | Skeletal muscle atrophy | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0003431 | Decreased motor nerve conduction velocity | Frequent (30-79%) |
| HP:0003444 | EMG: chronic denervation signs | Frequent (30-79%) |
| HP:0003470 | Paralysis | Frequent (30-79%) |
| HP:0003496 | Increased circulating IgM level | Frequent (30-79%) |
| HP:0004302 | Functional motor deficit | Frequent (30-79%) |
| HP:0004372 | Reduced consciousness/confusion | Frequent (30-79%) |
| HP:0007277 | Paucity of anterior horn motor neurons | Frequent (30-79%) |
| HP:0009053 | Distal lower limb muscle weakness | Frequent (30-79%) |
| HP:0010549 | Weakness due to upper motor neuron dysfunction | Frequent (30-79%) |
| HP:0010702 | Increased circulating antibody level | Frequent (30-79%) |
| HP:0011897 | Neutrophilia | Frequent (30-79%) |
| HP:0012229 | CSF pleocytosis | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0012692 | Focal T2 hyperintense thalamic lesion | Frequent (30-79%) |
| HP:0025143 | Chills | Frequent (30-79%) |
| HP:0040272 | Hyperintensity of MRI T2 signal of the spinal cord | Frequent (30-79%) |
| HP:0200149 | CSF lymphocytic pleiocytosis | Frequent (30-79%) |
| HP:0000639 | Nystagmus | Occasional (5-29%) |
| HP:0000708 | Atypical behavior | Occasional (5-29%) |
| HP:0001259 | Coma | Occasional (5-29%) |
| HP:0001266 | Choreoathetosis | Occasional (5-29%) |
| HP:0001276 | Hypertonia | Occasional (5-29%) |
| HP:0001287 | Meningitis | Occasional (5-29%) |
| HP:0001332 | Dystonia | Occasional (5-29%) |
| HP:0001336 | Myoclonus | Occasional (5-29%) |
| HP:0001337 | Tremor | Occasional (5-29%) |
| HP:0001762 | Talipes equinovarus | Occasional (5-29%) |
| HP:0002014 | Diarrhea | Occasional (5-29%) |
| HP:0002027 | Abdominal pain | Occasional (5-29%) |
| HP:0002060 | Abnormal cerebral morphology | Occasional (5-29%) |
| HP:0002071 | Abnormality of extrapyramidal motor function | Occasional (5-29%) |
| HP:0002098 | Respiratory distress | Occasional (5-29%) |
| HP:0002133 | Status epilepticus | Occasional (5-29%) |
| HP:0002179 | Opisthotonus | Occasional (5-29%) |
| HP:0002181 | Cerebral edema | Occasional (5-29%) |
| HP:0002203 | Respiratory paralysis | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Japanese encephalitis |
| Mondo ID | MONDO:0019209 |
| EFO | EFO:0007332 |
| MeSH | D004672 |
| Orphanet | 79139 |
| DOID | DOID:10844 |
| ICD-10-CM | A83.0 |
| ICD-11 | 961032639 |
| NCIT | C34577 |
| SNOMED CT | 52947006 |
| UMLS | C0014057 |
| MedGen | 4032 |
| GARD | 0006797 |
| MedDRA | 10014596 |
| NORD | 1088 |
| Is cancer (heuristic) | no |
Also known as: Encephalitis, Japanese · Japanese B encephalitis · JE
Disease family
This is a subtype of mosquito-borne viral encephalitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis › encephalitis › infectious encephalitis › viral encephalitis › mosquito-borne viral encephalitis › Japanese encephalitis
Related subtypes (4): st. Louis encephalitis, West-Nile encephalitis, la Crosse encephalitis, western equine encephalitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Japanese Encephalitis Virus, Inactivated | Approved (phase 4) |
| Satralizumab | Phase 3 (in late-stage trials) |
| Sodium Chloride | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ribavirin, Rituximab.
Clinical trials & evidence
Clinical trials
Clinical trials: 65.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 27 |
| PHASE4 | 15 |
| PHASE2 | 13 |
| Not specified | 9 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06678373 | PHASE4 | ACTIVE_NOT_RECRUITING | Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas |
| NCT00463476 | PHASE4 | COMPLETED | Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine |
| NCT00463684 | PHASE4 | COMPLETED | Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age |
| NCT01158599 | PHASE4 | COMPLETED | This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population |
| NCT01567865 | PHASE4 | COMPLETED | Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine |
| NCT01656200 | PHASE4 | COMPLETED | A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 |
| NCT01815073 | PHASE4 | COMPLETED | Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine |
| NCT01954810 | PHASE4 | UNKNOWN | Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children |
| NCT01981967 | PHASE4 | COMPLETED | Post-licensure Safety Study of IMOJEV® in Thailand |
| NCT02514746 | PHASE4 | COMPLETED | Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose |
| NCT02532569 | PHASE4 | COMPLETED | Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj |
| NCT02643433 | PHASE4 | COMPLETED | Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines |
| NCT02880865 | PHASE4 | COMPLETED | Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine |
| NCT04817917 | PHASE4 | UNKNOWN | Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province |
| NCT06331702 | PHASE4 | COMPLETED | Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) |
| NCT00314132 | PHASE3 | COMPLETED | Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. |
| NCT00314145 | PHASE3 | COMPLETED | A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX |
| NCT00594958 | PHASE3 | COMPLETED | Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 |
| NCT00595270 | PHASE3 | COMPLETED | Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 |
| NCT00595309 | PHASE3 | COMPLETED | Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 |
| NCT00595465 | PHASE3 | COMPLETED | Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 |
| NCT00595790 | PHASE3 | COMPLETED | Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 |
| NCT00596271 | PHASE3 | COMPLETED | Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 |
| NCT00604708 | PHASE3 | COMPLETED | Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 |
| NCT00605085 | PHASE3 | COMPLETED | Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 |
| NCT00735644 | PHASE3 | COMPLETED | Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines |
| NCT00776230 | PHASE3 | COMPLETED | Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling |
| NCT00938379 | PHASE3 | UNKNOWN | Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR |
| NCT01001988 | PHASE3 | COMPLETED | Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers |
| NCT01092507 | PHASE3 | COMPLETED | A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers |
| NCT01150942 | PHASE3 | COMPLETED | Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea |
| NCT01188343 | PHASE3 | COMPLETED | Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers |
| NCT01190228 | PHASE3 | COMPLETED | Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV |
| NCT01246479 | PHASE3 | COMPLETED | Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study |
| NCT01296360 | PHASE3 | COMPLETED | Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country |
| NCT01386827 | PHASE3 | COMPLETED | Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis |
| NCT01396512 | PHASE3 | COMPLETED | Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers |
| NCT01466387 | PHASE3 | COMPLETED | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
| NCT01662440 | PHASE3 | COMPLETED | Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects |
| NCT01900444 | PHASE3 | COMPLETED | Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| JAPANESE ENCEPHALITIS VIRUS, INACTIVATED | 4 | 3 |
| SODIUM CHLORIDE | 4 | 1 |
| YELLOW FEVER VACCINE | 3 | 3 |
| RABIES VACCINE | 3 | 1 |
| SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN | 3 | 1 |
| TYPHOID VI POLYSACCHARIDE VACCINE | 3 | 1 |